PDF-Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs PDF document

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability

Upload by pamella-moone
Published on 2014-11-14

Presentation Embed Code

<iframe width="560" height="315" src="https://www.docslides.com/embed/12066" frameborder="0" allowfullscreen></iframe>

Download Presentation

Download Presentation The PPT/PDF document "Guidance for Industry Expanded Access to..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs : Transcript

PDF-Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs PDF document

Presentation Embed Code

Download Presentation

Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs : Transcript

Related Contents

Guidance for Industry Complicated Intra Abdominal Infections Developing Drugs for Treatment

Guidance for Industry Contract Manufacturing Arrangements for Drugs Quality Agreements

Guidance for Industry Developing Products for Weight Management DRAFT GUIDANCE This guidance

Guidance for Industry Assessment of Abuse Potential of Drugs DRAFT GUIDANCE This guidance

Guidance for Industry Chronic Fatigue Syndrome Myalgic Encephalomyelitis Developing Drug

Guidance for Industry Naming of Drug Products Containing Salt Drug Substances DRAFT GUIDANCE

Guidance for Industry Applications for Premarket Review of New Tobacco Products DRAFT

Guidance for Industry Safety Considerations for Container Labels and Carton Labeling

Scientific Considerations in Demonstrating Biosimilarity to a Reference Product DRAFT

Guidance for Industry How to Comply with the Pediatric Research Equity Act DRAFT GUIDANCE

Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA DRAFT GUIDANCE

Guidance for Industry Considerations for the Design of Early Phase Clinical Trials of

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits

Guidance for Industry and FDA Staff Submissions for Postapproval Modifications to a Combination